Press Release

Assembly Biosciences Reports Updates on Corporate Progress and First Quarter 2020 Financial Results

May 7, 2020 at 4:05 PM EDT

-- Advancing the development of three clinical-stage core inhibitor candidates in HBV portfolio --
-- Cash position of $249 million projected to fund operations into 2022 --
-- Company to host HBV portfolio progress update call / webcast today at 1:30 pm PT / 4:30 pm ET --

SOUTH SAN FRANCISCO, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today reported financial results for the first quarter ended March 31, 2020 and provided an update on recent corporate progress.

“I am proud of the exceptional commitment and focus that our team has demonstrated during the first quarter, in light of the unprecedented events unfolding throughout the world and the healthcare sector with the COVID-19 pandemic. We have managed to achieve our key business objectives while keeping the health and safety of patients, study staff, and employees top of mind, and continuing to assess and adapt to this environment,” said John McHutchison, AO, MD, Chief Executive Officer and President. “Importantly, we have finalized the stopping criteria by which patients with chronic HBV infection in Study 211 will be transitioned off combination therapy with our core inhibitor candidate ABI-H0731 and a nucleos(t)ide therapy later this year. This is a critical next step in the development of hepatitis B therapies, as ours would be the first trial of a core inhibitor to stop therapy and monitor patients for potential sustained virologic response.”

First Quarter 2020 and Recent Highlights

HBV Portfolio

  • ABI-H0731: Assembly’s lead core inhibitor candidate
    • The Phase 2 open-label extension study (Study 211) is ongoing with subjects reaching 12-18 months of combination treatment with ABI-H0731 and standard-of-care nucleos(t)ide analogue reverse transcriptase inhibitor (NrtI) therapy.
    • Assembly has determined the stopping criteria by which it will begin transitioning patients off therapy, and these criteria have been discussed with its lead investigators and reviewed and agreed upon by the U.S. Food and Drug Administration (FDA).
    • Assembly has submitted an End of Phase 2 meeting request and briefing document for review with China regulatory authorities to plan for the initiation of studies aimed at supporting the registration of ABI-H0731 with NrtI for chronic suppressive therapy in China.
  • ABI-H2158, Assembly’s second-generation, more potent core inhibitor candidate, has completed the dose-ranging Phase 1b clinical trial and the Company has selected the 300 mg daily dose of ABI-H2158 to advance into Phase 2 development. The Company is preparing to initiate a multi-center, randomized, placebo-controlled Phase 2 trial evaluating ABI-H2158 with entecavir versus placebo with entecavir in approximately 80 treatment-naïve, HBeAg positive patients with chronic HBV infection.
  • ABI-H3733, Assembly’s third core inhibitor candidate, has continued to advance in development. A Phase 1 trial is now open for enrollment and will evaluate safety, tolerability, and pharmacokinetics following single ascending dose and multiple ascending dose administrations of ABI-H3733 in healthy subjects.
  • Additional information on the above, and Assembly’s other recent progress with its HBV core inhibitor portfolio, will be shared today at 1:30 pm PT during a conference call and simultaneous webcast (connection information provided below). The slides presented during the webcast will be available shortly after the call on Assembly’s website
  • In March 2020, research into the turnover and presumed half-life of covalently closed circular DNA (cccDNA) pools, which play a pivotal role in the establishment and persistence of HBV infection, was first published online in Hepatology, the journal of the American Association for the Study of Liver Diseases

Microbiome Portfolio

  • Preclinical data on Assembly Biosciences’ Microbiome program in ulcerative colitis (UC) were presented in a poster during Digestive Disease Week’s 2020 Virtual Meeting. A copy of the poster is available on Assembly Biosciences’ website. In addition, the abstract is scheduled for publication in the May online supplements to the journals Gastroenterology and GIE: Gastrointestinal Endoscopy.

Corporate Highlights

  • In March 2020, Jason Okazaki joined as Chief Legal and Business Officer.
  • In April 2020, Carl Henrik Enell joined as Senior Vice President, Corporate Development.

Upcoming Milestones

HBV Portfolio

  • ABI-H0731
    • Presentation of additional interim analyses from Study 211 at the European Association for the Study of the Liver’s (EASL) Digital International Liver Congress, rescheduled to August 27-29, 2020; abstracts were accepted as an oral presentation (HBeAg negative patients) and as a late-breaking poster (HBeAg positive patients).
    • Plan to begin taking patients off of combination therapy later this year, to then monitor for sustained virologic response.
  • ABI-H2158
    • Plan to initiate a Phase 2 clinical trial in the second quarter of 2020.
    • Presentation of Phase 1b clinical data on multiple dose cohorts accepted for inclusion at EASL as a late-breaking poster.
  • ABI-H3733
    • Continuation of ongoing Phase 1 clinical trial.
  • Proprietary In-House HBV DNA and pgRNA Assays
    • Poster presentation of Assembly’s highly sensitive assays at EASL.

Microbiome Portfolio

  • ABI-M201
    • Continuation of the ongoing multi-center randomized, placebo-controlled Phase 1b trial in patients with mildly to moderately active UC.
  • Microbiome Platform
    • Poster presentation of preclinical data from Assembly’s microbiome immuno-oncology program at the American Association for Cancer Research Virtual Annual Meeting II, June 22-24, 2020.
    • Expanded utilization of Assembly’s rational function-based microbial discovery platform and in-house high-quality manufacturing expertise to advance new proprietary live biotherapeutic consortium candidates for oncology and other disease indications.

First Quarter 2020 Financial Results

  • Cash, cash equivalents and marketable securities were $249.1 million as of March 31, 2020, compared to $274.0 million as of December 31, 2019. This cash position is projected to fund operations into 2022.
  • Revenues from collaborative research were $4.1 million for the three months ended March 31, 2020 compared to $3.9 million for the same period in 2019.
  • Research and development expenses were $23.0 million for the three months ended March 31, 2020, compared to $22.7 million for the same period in 2019. The increase was primarily due to an increase of $0.4 million in gross research and development expenses related to the Microbiome programs and a decrease of $0.1 million in research and development expenses related to the HBV programs. Research and development expenses include non-cash stock-based compensation expenses of $1.9 million for the three months ended March 31, 2020 and $2.7 million for the same period in 2019.
  • General and administrative expenses were $8.7 million for the three months ended March 31, 2020 compared to $9.5 million for the same period in 2019. General and administrative expenses include non-cash stock-based compensation expenses of $3.0 million for the three months ended March 31, 2020 and $3.8 million for the same period in 2019.
  • Net loss attributable to common stockholders was $26.7 million, or $0.76 per basic and diluted share, for the three months ended March 31, 2020 compared to $27.1 million, or $1.05 per basic and diluted share, for the same period in 2019.

Conference Call / Webcast Today
Assembly Biosciences is hosting a conference call and webcast today at 1:30 pm PT / 4:30 pm ET. The live audio webcast with accompanying slide presentation may be accessed through the “Events & Presentations” page in the “Investors” section of the Company’s website at Alternatively, participants may dial (866) 438-0453 (domestic) or (409) 220-9366 (international) and refer to conference ID 5156737. Due to current high volume accessing virtual events, participants are encouraged to connect at 1:15 pm PT / 4:15 pm ET to ensure a timely connection to the call or to utilize the webcast link for listen-only access.

The archived webcast will be available on Assembly’s website beginning approximately two hours after the event and will be archived and available for replay for at least 30 days after the event.

About Assembly Biosciences
Assembly Biosciences, Inc. is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly’s fully integrated platform, including a robust process for strain identification and selection, GMP manufacturing expertise and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. For more information, visit

Forward-Looking Statements
The information in this press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These risks and uncertainties include:  Assembly’s ability to initiate and complete clinical trials involving its HBV Cure and Microbiome therapeutic product candidates in the currently anticipated timeframes; safety and efficacy data from clinical studies may not warrant further development of Assembly’s product candidates; clinical and nonclinical data presented at conferences may not differentiate Assembly’s product candidates from other companies’ candidates; Assembly may not observe sustained virologic response in patients who stop therapy in Study 211; Assembly’s ability to maintain financial resources necessary to continue its clinical trials and fund business operations; any impact that the spread of the coronavirus and resulting COVID-19 pandemic may have on Assembly’s business and operations, including initiation and continuation of its clinical trials or timing of discussions with regulatory authorities; and other risks identified from time to time in Assembly’s reports filed with the U.S. Securities and Exchange Commission (the SEC). You are urged to consider statements that include the words may, will, would, could, should, might, believes, hopes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal or the negative of those words or other comparable words to be uncertain and forward-looking. Assembly intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. More information about Assembly’s risks and uncertainties are more fully detailed under the heading “Risk Factors” in Assembly's filings with the SEC, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Except as required by law, Assembly assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

(In thousands except for share and per share amounts)
    March 31,   December 31,
      2020       2019  
Current assets        
Cash and cash equivalents   $ 42,326     $ 46,732  
Marketable securities     206,803       227,311  
Accounts receivable from collaboration     3,055       3,374  
Prepaid expenses and other current assets     4,568       5,363  
Total current assets     256,752       282,780  
Property and equipment, net     1,780       1,830  
Operating lease right-of-use (ROU) assets     11,479       11,975  
Other assets     1,661       1,684  
Indefinite-lived intangible asset     29,000       29,000  
Goodwill     12,638       12,638  
Total assets   $ 313,310     $ 339,907  
Current liabilities        
Accounts payable   $ 2,104     $ 1,731  
Accrued clinical expenses     4,633       4,826  
Other accrued expenses     4,430       8,286  
Deferred revenue - short-term     6,715       6,411  
Operating lease liabilities - short-term     3,264       3,186  
Total current liabilities     21,146       24,440  
Deferred tax liabilities     2,531       2,531  
Deferred revenue - long-term     29,326       30,637  
Operating lease liabilities - long-term     8,539       9,082  
Total liabilities     61,542       66,690  
Commitments and contingencies        
Stockholders' equity        
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding            
Common stock, $0.001 par value; 100,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 32,624,725 and 32,558,307 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively     32       32  
Additional paid-in capital     717,898       712,807  
Accumulated other comprehensive loss     (86 )     (201 )
Accumulated deficit     (466,076 )     (439,421 )
Total stockholders' equity     251,768       273,217  
Total liabilities and stockholders' equity   $ 313,310     $ 339,907  

(In thousands except for share and per share amounts)
    Three Months Ended March 31,
      2020       2019  
Collaboration revenue   $ 4,081     $ 3,885  
Operating expenses:        
Research and development     23,046       22,704  
General and administrative     8,729       9,517  
Total operating expenses     31,775       32,221  
Loss from operations     (27,694 )     (28,336 )
Other income (expenses)        
Interest and other income, net     1,039       1,277  
Total other income     1,039       1,277  
Loss before income taxes     (26,655 )     (27,059 )
Income tax benefit     -       7  
Net loss   $ (26,655 )   $ (27,052 )
Other comprehensive (loss) income        
Unrealized gain on marketable securities, net of tax     115       108  
Comprehensive loss   $ (26,540 )   $ (26,944 )
Net loss per share, basic and diluted   $ (0.76 )   $ (1.05 )
Weighted average common shares outstanding, basic and diluted     35,079,756       25,668,798  


Assembly Biosciences, Inc.Amy Figueroa, CFA
Investor Relations Consultant
(415) 366-5158 

Solebury Trout
Luke Brown
(646) 378-2944


Source: Assembly Biosciences, Inc.